Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% ...

A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results ...

Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit ...

Lawmakers warn the arrangement Eli Lilly and Pfizer have with telehealth platforms may lead to conflicts of interest, subpar ...

Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

As part of its long-term investment in women’s sports, Eli Lilly will be present at the WNBA All-Star Game through breast ...

Eli Lilly has cleared a major hurdle in its bid to win European approval for its Alzheimer's disease drug Kisunla.

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics ...

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, ...

Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.